authors Cummings, J Petersen, R C Salloway, S Liana Apostolova, MD, MSc, FAAN Rabinovici, G D Atri, A Aisen, P Greenberg, S Hendrix, S Selkoe, D Weiner, M
Keywords Alzheimer’s disease Food and Drug Administration accelerated approval aducanumab amyloid imaging amyloid-related imaging abnormalities (ARIA) donanemab lecanemab magnetic resonance imaging (MRI) prescribing information